What Makes RESI Europe Stand Out

By Rikki Piccirillo, Marketing Manager, LSN

Rikki

We are excited to introduce RESI Barcelona 2024, where innovation converges with investment in Europe’s thriving life sciences ecosystem. Join us as we explore the dynamic opportunities highlighted by Greg Mannix, VP International Business Development at Life Science Nation.

RESI Barcelona 2024 combines in-person networking with a hybrid digital format, offering unparalleled access to over 300 early-stage companies. From the Innovators Pitch Challenge to engaging panels and workshops, RESI Barcelona promises a platform for startups to showcase cutting-edge technologies and connect with investors seeking the next big breakthrough.

English

Español

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Exhibit at RESI Europe 

By Cameron Hurlburt, Director of Business Development, LSN

RESI returns to Europe at the Hilton Diagonal Mar Hotel in Barcelona. This conference is a hybrid format; in person on Monday, June 17 followed by two days of virtual partnering. Past in-person RESIs boasted a vibrant network of service providers, including CRO/CMOs, non-profits, suppliers, and professional services like law firms and banks. These service providers have played an essential role in the RESI ecosystem, and we are pleased to welcome them back with more offerings that include onsite and digital formats to promote their services and connect them with early-stage startups who need them.

DSC1819McDermott Will & Emery a global law firm exhibited at RESI South on March 25, 2024.

RESI’s unique value to its service providers is its dedication to early-stage companies in life science and healthcare. These startups have specific needs that make them ideal clients for a variety of providers. CRO/CMOs attend RESI to connect with preclinical therapeutics. Lab services with valuable R&D space, banks with life science-specific benefits, and law firms specializing in IP, term sheet negotiations, and more exhibit at RESI to connect with these founders who seek their services.

DSC9738-scaledCambridge Innovation Center exhibited at RESI Boston on June 5, 2023.

RESI exhibition includes a table for promotion and networking in the exhibit hall. Exhibitors also have their logo featured prominently on the RESI website, program guide, and onsite signage. The exhibitor package also includes a complimentary registration to participate in the partnering platform and attend all conference events. Interested in reaching a broad audience of early-stage entrepreneurs at RESI Europe Barcelona? Contact us to learn more!

RESI-Europe-2024-Banner-1100pxw

IPC Winner, Sanguina, Finds Connection at RESI South 

Interview with Erika Tyburski, CEO at Sanguina and Maria Thacker-Goethe, President & CEO at Georgia Bio By Caitlin Dolegowski, Marketing Manager, LSN

Erika TyburskiErika Tyburski
Maria Thacker-GoetheMaria Thacker-Goethe
CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): Please introduce us to Sanguina and the company’s technology (and curious about the naming of your company).

Erika Tyburski (ET): Hi Caitlin. Sanguina means blood in Latin and is also derived from the English word sanguine- or relaxed. I co-founded Sanguina to make accessible tools to learn more about your health. We have a focus on blood health, and making tools that tell you something about blood. We are passionate about blood because it often changes first in response to a stress on the system- a cold, a deficiency, or a chronic disease. This is why blood testing is often used for diagnoses. Our first platform is called AnemoCheck for accessible and rapid anemia management. We recently received FDA-clearance on a home test for hemoglobin level determination and have a complementary smartphone application for determining likelihood of anemia based on the paleness of fingernails via a fingernail selfie.

CD: Maria, please introduce us to Georgia Bio. RESI South took place in Atlanta and there were many companies from Georgia represented RESI. Tell us about the life sciences ecosystem in Georgia and exciting companies emerging, such as Sanguina.

Maria Thacker-Goethe (MT): Georgia Bio is the life science association focused on enhancing the innovation environment in Georgia. Our main goals are advocating for favorable policies, linking members with funding and partners, and supporting workforce development in the state.

Sanguina is one of our standout companies, but it’s not alone. At the RESI conference, we also had Andson Biotech, Aruna Bio, and Emtherapro presenting to the 350 attendees. These companies represent our growing ecosystem. The life sciences sector in Georgia has seen significant growth, with a 20% increase in jobs since 2015, totaling 11,225, and generating a total economic impact of $50.2 billion, according to Biopharma Reporter. Georgia is emerging as a prominent life science hub.

CD: Maria, I know you have been to RESI before, Erika, this was your first conference. What are your experiences at RESI? What worked well for you both at RESI South?

ET: The event was very efficient. The networking platform enabled meetings to be made ahead of the event and the rapid 20-minute meetings allowed me to meet with many parties in a short amount of time. Talk about bang for buck! I found myself re-connecting with people that have seen me grow locally and meeting new people in the southeast region. I particularly enjoyed the pitch session and constructive questions given to me by the digital health panel.

MT: First off, I had a great experience at the RESI South event last month. My team and I had more than a dozen meetings with life science companies in the state. Although Georgia has all the seeds needed to grow a robust ecosystem, one of the big gaps is venture funding. That is why the state associations partnered with Life Science Nation. We are excited about our partnership and look forward to even stronger future events.

CD: Erika, what stage of fundraising is Sanguina in and what are your goals in 2024?

ET: We have closed our first priced round. Sanguina is fortunate enough to have completed our raise and we are looking to go to work and generate recurring revenue this year and next. Sanguina is primarily a B2B company, so I am aiming to onboard several new customers and execute contracts for custom versions of our products. I look forward to profitability, with my next round focused on growth.

CD: Congratulations on your second-place finish at RESI JPM’s Innovator’s Pitch Challenge (IPC)! What do you think was the key to your success and standing out at RESI JPM?

ET: I’ve pitched a lot. I’ve been given thousands of questions on Why? How? When? And I’ve learned in that time to be as honest as possible. I’m not afraid to say: “I’m working on that answer”, while also acknowledging that “I’ve faced many challenges, and know how to overcome” I think investors and experts in my industry appreciate my candor. Additionally, I learn by doing, so throughout the years, I haven’t been afraid to Just Do It. I’ve learned how to run clinical studies, how to execute a regulatory strategy, how to raise money, how to close that first customer.

CD: What advice would you like to give to fellow entrepreneurs about RESI conferences?

ET: Have confidence in what you do and know. Be humble and talk to everyone, you never know what one new connection will lead to. And use the networking platform, of course!

MT: My biggest piece of advice is to use the partnering system to meet investors. Over 200 investors attended RESI South, either in person or virtually, which the Southeast has never seen. These investors want to meet with you to get to know you and your business.


If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the RESI Europe 2024 IPC taking place June 17-19 with a 1-day in-person conference follow by 2-day virtual partnering at Hilton Diagonal Mar Barcelona in Barcelona, Catalonia, Spain. Applications are accepted on a rolling basis, so get your application submitted today!

RESI-Europe-2024-Banner-1100pxw

Register-now-button-new

Confirmed Early-Stage Investors Attending RESI Europe in June

By Faith Patenaude, Investor Research Analyst, LSN

Faith

Life Science Nation (LSN) is thrilled to announce the third RESI conference of the year, which will take place in Barcelona, Spain. We invite you to join us in person on Monday, June 17th, at the Hilton Diagonal Mar Barcelona, and virtually on June 18th-19th. Monday’s schedule includes engaging entrepreneur workshops, insightful investor panels, and our highly favored Innovator’s Pitch Challenge (IPC). One-on-one partnering opportunities will be available throughout the three-day event.

RESI Europe stands as an exceptional platform for early-stage life science companies, providing unparalleled opportunities to engage and connect with a diverse array of European and global investors. The LSN investor research team has been diligently working to invite investors, including CVC, angel groups, family offices, venture capital funds, big pharma, and more. Each investor has undergone thorough vetting to ensure alignment with company profiles, guaranteeing a distinctive edge over other conferences and fostering high-caliber attendance. RESI’s partnering platform welcomes the opportunity for you to connect with investors with aligned interests and of best fit. RESI offers an outstanding chance for early-stage startups, service providers, and investors to cultivate meaningful connections and broaden their network within the life science sector.

Save up to €500 with our super early bird rate – ending tomorrow, Friday April 19th. Sign up now and join the featured investors below.

CI04182024

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Decoding the Mysteries Behind the Low Success Rate of Life Science Startups

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

The life science industry is a hotbed of innovation and groundbreaking research, but its startup success rate paints a sobering picture, ranging from 1 to 5%. What lies behind this alarming statistic? As CEO of Life Science Nation (LSN) and the mastermind behind the Redefining Early Stage Investments (RESI) partnering conference, I have witnessed firsthand for over a decade the multifaceted complexities that plague the entrepreneurial journey and produce these dismal metrics for life sciences startups. Below is a table that outlines the challenges for startups launching a fundraising campaign.

Critical Pitfalls Misunderstanding the Ante into the Game
Subpar Ideas Not all ideas are created equal. Some startups force-fit innovation without validating market fit, others create solutions in search of a problem without a clue about the business model, and still, others pay scant attention to scaling customer acquisition and channel. Startups require evidence of a current unmet need and a market.  
Inexperienced Teams Startup teams without experience navigating the complexities of launching and scaling a business often find themselves ill-equipped to overcome the challenges. This often leads to costly mistakes that can cause the business to fail, despite the potential merit of the technology.
Mismatched Skill Sets CEOs sometimes fall into the trap of hiring team members who mirror their skill sets rather than seeking complementary expertise, leading to gaps in essential capabilities.  
Underestimating Scale-Up Challenges Creating a prototype is a crucial step and presenting initial validating data does not always translate to success scaling up from proof of concept to full-fledged products.
Navigating Support Ecosystems  The landscape of support networks for startups, including incubators, accelerators, and innovation clusters, can be a double-edged sword. While valuable resources abound, not all mentors and advisors possess the practical experience to guide startups effectively. Hence we see cookie-cutter, non-personalized pitch decks that cover “problem, solution, addressable market,” providing no insight into the founder,  team, and genesis of technology.  
Preparing and Executing a Fundraising Campaign  Startups need a compelling story, a global target list of at least 800 partners to go after, a CRM to organize and manage the list, and someone who understands social media and is a people person to set up meetings and schedule follow-ups. It takes 9-18 months if you are lucky. 

Despite these challenges, I remain optimistic about the future of life science entrepreneurship. The key lies in mastering the art of fundraising—a process that demands a nuanced understanding of global markets, investor relations, and strategic messaging. Launching a successful fundraising campaign requires meticulous planning and execution. Cultivating a targeted list of potential partners and investors tailored to the startup’s stage of development and product offering is crucial. This approach starkly contrasts the indiscriminate spamming tactics often employed by ill-prepared startups.

Herein lies the significance of initiatives like Life Science Nation (LSN) and the RESI partnering series. These platforms provide invaluable resources and networking opportunities for startups seeking to navigate the complex landscape of fundraising and industry partnerships. LSN offers Entrepreneurial Education Classes for Preparing and Executing a Successful Global Partnering Campaign. A database of investors and licensing partners that fit your stage of development and product and can be integrated with your CRM, and the international RESI conference series that get you out of your region and into the international marketplace where you can attend in-person meetings and also virtual meetings with a bevy of potential investor from around the world.

Mastering the Art of Fundraising

Securing funding necessitates a nuanced understanding of global markets, investor relations, and strategic messaging. LSN products combined with the RESI partnering series offer invaluable resources and networking opportunities for startups navigating the complex fundraising landscape. By embracing strategic fundraising methodologies, startups can amplify their chances of success amidst the industry’s burgeoning innovation.

Closing the Funding Gap in Europe 

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

We have all heard that 2023 was a difficult year for early-stage funding. One theory is that pharma M&A activity lagged and reduced the incentive for investment into new life sciences funds, combined with the general expectation that a global recession was coming, leading VCs to invest mainly in their current portfolio companies and not so much into new ventures.

Thankfully, the recession didn’t materialize, and some pharma execs point to favorable conditions that connote an uptick in M&A activity that will bring a kind of trickle-down effect and benefit the early-stage folks. The impressions I have gathered at this year’s first two RESI conferences have been upbeat about the months ahead.

In Europe, I have always been impressed by the government-backed grant and other funding programs available in each country to help the earliest startups get off the ground. These programs are augmented by excellent EU initiatives like Horizon and EIT. But what happens when European biotech and MedTech startups need to raise larger amounts to move their technologies along on the road to commercialization?

That’s where companies hit a wall; there isn’t enough venture capital on the old continent to fund all the fantastic technologies being developed. A European investor recently told me about one of his very successful portfolio companies that was at a stage where they needed to raise a significant round. Having difficulty finding sufficient co-investors in Europe, they eventually brought in a US investor to complete the round. This was only possible thanks to the European and US investors already having a relationship.

At LSN it has long been our goal to facilitate cross-border relationships, not only between companies and investors, but also between investors from different regions or countries. RESI Europe – Barcelona on June 17-19, 2024 is shaping up to be an especially international gathering. Hope to see you there!

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Hot Investor Mandate: VC Firm Invests in and Builds Companies in Healthtech and Tech-Enabled Health Services, Seeking Technologies in USA & Canada

A USA-based VC firm builds and invests in companies in the healthcare sector, with a focus on personalized health and consumer health.  The firm typically invests in seed or Series A rounds and initial investments range from  $150,000-$1.5 million, with a potential commitment of up to $5 million over the life of the investment.  The firm invests in the USA and Canada. 
 
The firm focuses on healthtech and tech-enabled health services. The firm is interested in disease management (includes chronic, autoimmune, mental/behavioral, neurology, microbiome, and digital therapeutics), care management, precision medicine, remote monitoring (including pushing the point of care into ambulatory settings such as retail clinics and the home), population health management (including underserved patients and Medicaid recipients, and patients living in areas outside the East Coast and West Coast).  The firm is also open to investing in devices and diagnostics, but only if they are targeted at consumers/patients as users, rather than physicians. 
 
The firm generally does not invest in companies that face FDA regulatory risk; the firm invests in companies with products that are already approved or do not require FDA approval. The firm prefers to invest in revenue generating companies but will consider startups that will begin to generate revenue in 6-12 months.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.